Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On January 10, 2011, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in share interests for specific individuals. This increase resulted from the re-investment of dividends paid to shareholders on January 6, 2011, at a price of £12.51 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in ordinary share interests via dividend re-investment.
- Share Price: £12.51 per share.
- Dividend Date: January 6, 2011.
- Notification Date: January 10, 2011.
- Individuals Notified: Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, and Mrs V A Whyte.